00883nas a2200337   4500000000100000008004100001260001300042653002600055653002600081653001900107653002500126653003000151653002200181653001100203653002300214653001200237653001600249653002500265653001400290653001300304653002500317100001700342700001200359700001300371700001500384245007400399856004100473300001000514490000700524022001400531       1999                            d  c1999 Sep10aAnti-Bacterial Agents10aAnti-Infective Agents10aCohort Studies10aConfidence Intervals10aDrug Therapy, Combination10aFollow-Up Studies10aHumans10aLeprostatic Agents10aleprosy10aMinocycline10aMycobacterium leprae10aOfloxacin10aRifampin10aSecondary Prevention1 aRevankar C R1 aPai V V1 aSamy M S1 aGanapati R00aSingle-dose treatment for paucibacillary leprosy; field implications.  uhttp://ila.ilsl.br/pdfs/v67n3a15.pdf  a312-40 v67  a0148-916X